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At present it is assumed that intracellular
metabolism is essentially a collective chain of
specific biochemical processes, each mediated by
specific biologic catalysts, and that promotion
of cell life depends upon the continuous activity
of these agents (Dixon and Webb (1)). Further,
it is postulated that enzyme contents of serum
represent enzyme in transit from living healthy
cells.
Alterations in enzyme activity in serum,
therefore, reflect and depend upon physiologic
alterations or actual destruction of selective
tissues with consequent interference with intra-
cellular metabolism and liberation of intracellular
enzymes into this accessible channel. A rise in
circulating content of an enzyme, therefore,
may denote its escape as a result of damage of
the primary source, the degree of elevation being
related to both degree of damage and the relative
concentration of enzyme in the primary source.
With this concept and with the availability of
several sensitive tests, quantitative estimations
of enzymatic activity in biologic fluids have been
utilized clinically in diagnosing and assessing the
prognosis of many diseases. Transaminases are
enzymes which catalyze the reversible transfer of
an alpha amino group from an amino acid to an
alpha keto acid.
Glutamic Oxalacetic (GOT)
Acid + Acid
aminase (SGPT) are two of these important
enzymes. They are present in considerable
amounts in animal and human tissues; and in
lesser amounts in the blood (2). The liver is the
second organ after the heart in its concentration
of the enzyme SGOT (3, 4). Liver damage (5, 6,
7, 8) and metastatic nialignancy (9, 10) have
been found to be associated with increase in
SGOT. The values of the enzymatic activity
decrease with clinical improvement and rise
again during relapses (11). Pathologic altera-
tions in transaminase activity can be produced
by cardiac disease (12, 13, 14), muscular disease
(15, 16, 17), shock or any acute hemolysis (4).
SGPT in tissues has been found in the following
descending order of concentration: liver, kidney,
heart skeletal muscles, pancreas and serum (18).
The enzymes have been demonstrated in skin
by Marsilii and Branzi (19). Only a few reports
(20, 21) have been made on transaminases in
skin diseases. Weber (1958, 1959) studied SGOT
in serum and cantharidin blister fluid and in
scales in thirty patients with skin diseases.
Weber and Theisen (22) have also studied
SGPT in twenty cases of dermatitis and nine
sufferers from bullous diseases. Dc Morages,
Perry and Fleischer (23), Siekert and Fleischer
(15) and Moore, Birchall, Hoarack, and Bateson
(24) studied SGOT in a number of cases of active
dermatomyositis. Tickner, Mier and McCabe
(25) studied SGOT and SGPT in a group of skin
diseases (psoriasis, eczema, exfoliative derma-
titis, atopic dermatitis, seborrheic dermatitis,
lichen planus, pemphigoid, pemphigus vulgaris,
systemic and discoid L.E., mycosis fimgoides,
dermatomyositis, Hodgkins disease, epithelioma,
photosensitivity, dermatitis papulosa nigra,
vitiligo, and pemphigus foliaceus).
In spite of the considerable work done in
testing the activity of transaminases in various
pathological conditions and the few reports on
transaminases in certain skin diseases, no studies
have been carried out on cases of xeroderma
pigmentosum (x.d.p.). Having 33 cases of x.d.p.
available for study we thought an investigation
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TABLE I
Serum glutamic oxalacetic transaminase in 33 cases x.d.p., 30 cases of their normal relatives and 10 control
normal subjects
Case No Normal Control
Normal Relatives X.D.P.
Fathers Mothers Brothers & Mild cases Severe cases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
8.7
4.3
13.1
21.2
15.8
19.4
14.6
26.3
11.8
19.2
14.6
5.1
9.3
30.0
4.5
15.3
4.9
7.2
20.1
10.3
10.7
7.2
13.6
20.5
8.9
34.4
14.8
5.9
6.9
11.8
12.8
5.9
15.4
27.8
19.2
8.4
11.2
16.7
14.9
5.3
60.4
40.1
59.2
28.1
48.5
82.6
19.6
73.1
11.9
25.6
62.4
14.5
38.1
44.2
40.2
46.6
71.4
69.1
84.2
67.4
58.4
26.5
95.3
82.1
104.0
53.4
33.4
60.5
81.1
73.8
59.0
124.2
71.7
Range 4.3—26.3 4.5—30.0 5.9—34.4 5.3—27.8 11.9—82.6 26.5—124.2
Mean value 15.4 12.1 13.5 13.8 43.4 71.5
TABLE II
Serum glutamic pyruvic transaminase in. 33 cases of x.d.p., 30 cases of their normal relatives and in 10
control normal subjects
Case No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Normal Control
12.2
6.8
9.1
11.4
18.2
8.7
4.5
13.1
23.6
4.0
Normal Relatives X.D.P.
Fathers
9.2
15.4
6.1
21.0
7.3
24.0
5.2
10.5
4.8
8.3
Mothers
5.6
13.2
9.7
14.3
6.8
15.4
24.9
11.8
16.9
11.5
Brothers &
15.9
6.3
15.4
10.1
4.9
7.1
15.2
22.9
5.5
19.1
Mild cases
81.1
35.2
75.4
20.2
36.5
109.6
19.7
80.5
38.6
9.8
78.6
54.3
16.1
29.3
44.8
53.0
Severe cases
53.6
108.2
64.5
47.6
62.4
56.4
118.5
41.2
151.4
51.4
66.4
99.4
63.5
66.3
57.2
140.4
88.7
Range 4.0—23.6 4.8—21.0 5.6—24.9 4.9—22.9 9.8—109.6 41.2—151.4
Meanvalues1
11.2 11.2 13.0 12.2 48.9 78.7
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of enzymes of the skin in this disease and an
attempt to correlate the findings with the
clinical course would be of interest.
MATERIAL AND METHOD
The subjects for the study were 33 patients with
xeroderma pigmentosum (x.d.p.) of ages ranging
from 4—32 years (El-llefnawi et at (26, 27, 28).
Nineteen were males and 14 females. Of their
parents and normal relatives, thirty patients were
also studied. Ten normal subjects of both sexes
were selected for the control group. These control
subj ects were carefully examined to make sure
that they had had no disease past or present that
might affect the estimations. Fasting venous blood
samples were collected. All samples of blood were
taken with a dry needle and syringe at 8 a.m. The
blood was placed in a dry test tube, allowed to
clot and the serum was separated by centrifuga-
tion.
The method used for the estimation of serum
glutamic oxalacetic transaminase was that of
llJmbreit et at (29). Olutamic pyruvic transaminase
was determined by the method of Reitman and
Frankel (30).
A reference curve is constructed using a series
of aqueous pyruvic acid solutions (as sodium
pyruvate) ranging from 0—50 ug/ml. The results
were expressed as colorimetric units. One unit is
defined as the activity of 1 ml of serum which will
form an amount of color complex in 20 minutes at
25° C (±2° C) equivalent to 1 ug/ml of pyruvic
acid.
REsULTs
The results of SOOT in 10 normal controls
ranged from 4.3 to 26.3 with a mean value of 15.4
units (this is in agreement with the normal range
obtained for Egyptians in previous studies)
(31, 32, 33). The results obtained for the normal
relatives were found to be in the normal range.
The results obtained ranged from 4.5 to 30.0,
5.9—34.4 and 5.3—27.8, with mean values of 12.1,
13.5 and 13.8 units respectively.
The values for SOOT in xeroderma pigmen-
tosum patients were divided into two groups:
The first group "A" consisted of 17 severe cases
showing marked atrophy of skin, ulcerations,
eye complications and malignancy. The results
obtained for SOOT for this group ranged from
26.5 to 124.2 units with a mean value of 71.5
units. Only two cases had SOOT values near the
higher level for normals or slightly above. Twelve
cases (70.6%) showed SOOT results markedly
higher than normal, with values ranging from
53.4—84.2 with a mean of 69.4 units; in three
cases (17.6%) the values were extremely high
95.3, 104.0 and 124.2 units.
The second group "B" consisted of 16 mild
cases demonstrating pigmentation, dryness,
telangiectasia of exposed skin and some warty
growths in addition to photophobia.
Six cases (37.5%) in this group gave SOOT
values within normal range, five cases (31.25%)
gave slightly raised values 40.1, 40.2, 44.2, 46.6
and 48.5, and the remaining five cases (31.25%)
gave markedly raised values ranging from 59.2—
82.6 with a mean of 67.5 units.
The values for SOFT in 10 normal controls
ranged from 4.0 to 23.6 with a mean value of
11.2 units. This is in agreement with the normal
range 5.0—21.0 with a mean of 10.7 obtained by
Tickner et at (25) and 3.0—30.0 with a mean of
13.0 obtained by Velon and Santhanagopolan
(34).
The results for the normal relatives were also
found to be in the normal range, 4.8—21.0, 5.6—
24.9 and 4.9—22.9 with mean values of 11.2,
13.0 and 12.2 respectively. In cases of group "A"
of x.d.p. studied, the SOFT was found to be
raised in 11 cases (64.7%) ranging from 41.2—
66.4 with a mean of 57.3 and grossly raised in 6
cases (35.4%) ranging from 88.7—151.5 with an
average of 117.8 units. In cases of group "B" of
x.d.p., the SOFT was found to be within normal
ranges in 4 cases (25.0%) with a mean value of
16.45, moderately increased in 4 cases (25.0%)
with average of 29.3—38.6 and a mean of 34.9,
markedly increased in 7 cases (43.7%) with a
range of 44.8 to 81.1 with a mean of 66.8 units
and grossly raised in one case (6.25%) with a
value of 109.6 units.
DIscussIoN
The present study revealed that the SOOT
and SOFT in the normal relatives of the 33
cases of xeroderma pigmentosum reported by us
is within normal range. Our normal data are in
agreement with the reports of previous workers
in Egypt (31, 32, 33) and abroad (34). In the
x.d.p. patients the usual routine liver function
tests were done together with serum trans-
aminases estimations. These liver function tests
were cephalin cholesterol flocculation, bilirubin,
alkaline phosphatase and thymol turbidity.
The results were normal in all cases examined.
Since the study of serum transaminases SOOT
and SOFT is being widely used in the assessment
482 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
of hepatie function (Worblewski (35)), the
finding of normal liver function tests in eases of
x.d.p. studied indicates that the increase in the
transaminases is not essentially of hepatie
origin.
In the 33 eases of x.d.p. the SGOT was found
to be within normal values in 18.2%, slightly
increased in 21.2%, markedly increased in 51.5%
and grossly increased in 9.1%. On the other hand
the SGPT in the 33 eases of x.d.p. was found to
be within normal in 12.1%, slightly increased in
12.1%, markedly increased in 54.5% and grossly
increased in 21.3% of the cases. Tickner et at
(25) studying SGOT and SGPT in a variety of
skin diseases reported an increase of SGOT in
22% of the eases and an increase of SGPT in 11%
of the eases. The findings of high SGOT and
SGPT in the markedly photosensitive patients of
x.d.p. to be in agreement with the findings of
Tickner et at (25) in photosensitivity, not includ-
ing x.d.p. Moreover the increase in SGOT and
SGPT covered a greater percentage of the cases.
Again we observed that the SGPT is more often
affected than the SGOT. This observation is in
agreement with that of Tiekner et at (25) to the
effect that SGPT is more often abnormal than
SGOT in skin diseases. It is worthy of note that
the extent of rise in SGOT and SGPT bears some
relationship to the severity of the disease, early
eases being the least affected.
sUMMARy
1. Serum glutamie oxalacetic transaminase
(SGOT) and serum glutamie pyruvic trans-
aminase (SGPT) were estimated in 33 cases of
xeroderma pigmentosum (x.d.p.), 30 eases of
their apparently normal relatives and 10 normal
controls.
2. SGOT and SGPT values for the relatives
were within normal.
3. SGOT was grossly increased in 9.1%,
markedly increased in 51.5%, slightly increased
in 21.2% and normal in 18.2% of the ease of
x.d.p.
4. SGPT was grossly increased in 21.3%,
markedly increased in 54.5%, slightly increased
in 12.1% and normal in 12.1% of the cases of
x.d.p.
5. SGPT was more often affected than SGOT.
6. The extent of rise in SGOT and SGPT
bears some relationship to the severity of the
ease.
7. Liver function tests yielded normal values
in the cases of x.d.p., ruling out the possibility of
hepatic origin for increment in serum trans-
aminases.
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